Some traders are opting to directly short IBB where “15 percent of all the shares outstanding — $665 million worth — are short,” according to Bloomberg.

While investors are departing biotech ETFs, that does not mean they are discarding all health care ETFs. Already one 2014 most prolific asset-gathering groups among sector funds, broader and non-biotech niche health care ETFs have continued seeing inflows even as biotech funds have wilted. [Health Care ETFs Survive Biotech Slump]

For example, the Health Care Select Sector SPDR (NYSEARca: XLV), the largest health care ETF, has pulled in almost $562 million since Feb. 28. The $718.1 million iShares U.S. Medical Devices ETF (NYSEArca: IHI), which printed several new all-time highs last week, has added more than $30 million in assets since the end of February.

iShares Nasdaq Biotechnology ETF

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.